Updated results from the Phase III ELATIVE trial reveal Iqirvo (elafibranor) significantly reduced fatigue in patients with ...

Linerixibat, an investigational oral ileal bile acid transporter (IBAT) inhibitor, improved cholestatic pruritus in patients ...

Interim results from the ongoing Phase III ASSURE trial demonstrated that Livdelzi maintained a consistent biochemical ...

Updated GLISTEN trial results presented at EASL 2025 confirm that the IBAT inhibitor linerixibat significantly improved worst ...

Seventy percent of patients treated with volixibat experienced a ≥50% reduction in serum bile acids - Volixibat treated ...

The GLISTEN trial of GSK's linerixibat has shown that the oral ileal bile acid transporter (IBAT inhibitor was signposted as ...

Living with primary biliary cholangitis (PBC) can be an isolating experience,” explains Dilek, a mother of two from Germany who suffers from the rare chronic liver disease.

Galmed Pharmaceuticals Ltd. (NASDAQ: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company for cardiometabolic diseases and GI oncological indications announced today results ...

The phase 3 GLISTEN trial has been evaluating the candidate in adults with PBC and cholestatic pruritus, or relentless itch, ...

A low-FODMAP (fermentable oligosaccharides, disaccharides, monosaccharides, polyols) diet can improve patients' irritable ...

French drugmaker Ipsen (Euronext: IPN) today announced new data from two late-breaking presentations on Iqirvo (elafibranor) ...